-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Speaker

Program: Continuing Conversations with the Speakers
Session: Continuing Conversations with the Speakers on Harnessing T cells in Therapy of Hematologic Malignancy
Sunday, December 6, 2015, 11:15 AM-12:15 PM
W303, Level 3 (Orange County Convention Center)

Dirk Hans Busch, MD

Institute for Medical Microbiology, Immunology and Hygiene, Technische Universitat Munchen, Munich, Germany

Disclosures: Busch: STAGE cell therapeutics: Other: I was share holder of STAGE cell therapeutics, a company that was recently bought by Juno therapeutics. . Off Label Use: CD19 CAR T cells.

See more of: Continuing Conversations with the Speakers on Harnessing T cells in Therapy of Hematologic Malignancy
See more of: Continuing Conversations with the Speakers
Previous Presentation | Next Presentation >>